National Institutes of Health: Melanoma trials

The registry lists 220 Melanoma studies with National Institutes of Health as lead sponsor. 14 are open to participants now and 92 have results posted.

Early Phase 1 1Phase 1 66Phase 2 147Phase 3 10No phase 18(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of UCN-01 in Metastatic MelanomaTerminatedNCT00072189Phase 2Results posted
• Peptide Vaccination for Patients at High Risk for Recurrent MelanomaCompletedNCT00059475Phase 2Results posted
• Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026221Phase 2Results posted
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
• Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaCompletedNCT00003895Phase 2Results posted
• Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedNCT00001832Phase 2Results posted
• The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)SuspendedNCT04866810Not applicable
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaActive, not recruitingNCT04708418Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2
• In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingNCT02196181Phase 2
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingNCT01989585Phase 1/2
• Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989559Phase 1
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWithdrawnNCT01851408Phase 2
• Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTerminatedNCT01835184Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Vemurafenib and White Blood Cell Therapy for Advanced MelanomaTerminatedNCT01585415Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerTerminatedNCT01457131Phase 1
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingNCT01364051Phase 1
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting BeadsTerminatedNCT01336985Phase 1
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaActive, not recruitingNCT01303341Phase 1
• RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by SurgeryWithdrawnNCT01216787Phase 2
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerCompletedNCT01021059Phase 1
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)CompletedNCT00923169Phase 1
• Sun Exposure and Melanoma in Agricultural WorkersCompletedNCT00901966
• Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Early Phase 1
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaCompletedNCT00349206Phase 1
• Molecular Epidemiology of Cutaneous Malignant MelanomaCompletedNCT00341991
• Genetic Analysis of Familial MelanomaCompletedNCT00339404
• Family Study of Melanoma in ItalyCompletedNCT00339222
• Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical TrialCompletedNCT00316901Phase 2
• Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerCompletedNCT00304460Phase 1
• Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic MelanomaTerminatedNCT00303836Phase 2
• LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By SurgeryCompletedNCT00295958Phase 2
• Natural History Study of Moles and Suspicious MelanomaCompletedNCT00288938
• Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaCompletedNCT00288041Phase 2
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00255762Phase 2
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
• Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaTerminatedNCT00138229Phase 2
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00091338Phase 1
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT00091104Phase 1
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedNCT00089063Phase 2
• Tanespimycin in Treating Patients With Stage III-IV MelanomaTerminatedNCT00087386Phase 2
• Vaccine Therapy in Treating Patients With Metastatic MelanomaTerminatedNCT00087373Phase 2
• Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00085462Phase 1
• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Cilengitide in Treating Patients With Unresectable or Metastatic MelanomaTerminatedNCT00082875Phase 2
• Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedNCT00080353Phase 2
• Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00079144Phase 2
• Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaCompletedNCT00077532Phase 2
• Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaCompletedNCT00072163Phase 2
• Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
• Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic MelanomaCompletedNCT00072085Phase 2
• A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular MelanomaCompletedNCT00062933Phase 2
• Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic MelanomaCompletedNCT00062036Phase 1/2
• Tipifarnib in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00060125Phase 2
• Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00058279Phase 1/2
• Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00054535Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• BMS-247550 in Treating Patients With Stage IV MelanomaCompletedNCT00036764Phase 2
• Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00032045Phase 2
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Eligibility Screening for the NIH Intramural Research Program Clinical ProtocolsCompletedNCT00026754
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026143Phase 2
• Isotretinoin in Preventing Skin CancerCompletedNCT00025012Not applicable
• PS-341 in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00024011Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous TreatmentCompletedNCT00022438Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00021164Phase 2
• Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00020540Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT00020475Phase 2
• Vaccine Therapy in Treating Patients With Refractory Metastatic MelanomaCompletedNCT00020397Phase 2
• Vaccine Therapy in Treating Patients With MelanomaCompletedNCT00020358Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00019994Phase 2
• Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic MelanomaCompletedNCT00019890Phase 2
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00019734Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019721Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019669Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019487Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019448Phase 2
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell CancerCompletedNCT00019396Phase 2
• Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic MelanomaCompletedNCT00019383Phase 2
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019214Phase 1/2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic MelanomaCompletedNCT00019175Phase 1